ArticleJournal of materials science. Materials in medicine2025
Bromelain-functionalized omega-3 nanocarriers for targeted icariin delivery: a multifunctional shield for cardiac repair in doxorubicin-induced injury.
Article in Journal of materials science. Materials in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The major loss of cardiomyocytes caused by several cardiovascular diseases as myocardial infarction, increases the incidence of heart failure. Thus, there is an urgent need to develop novel therapies that can enhance angiogenesis and decrease the rate of cardiac cell apoptosis. The use of nanoparticles that can passively target infarcted myocardium can be appealing. Icariin is a natural product with various cardioprotective properties that can be encapsulated within nanostructured lipid carriers (NLCs) to enhance its therapeutic effect. Incorporating bioactive excipients such as omega-3 oils and bromelain into the NLC formulation can potentiate its cardioreparative effects. Therefore, the use of such nanoformulation can be an attractive option to minimize cardiac damage. Optimized bromelain-coated and uncoated NLCs loaded with icariin were successfully developed, demonstrating efficient bromelain surface modification, high drug entrapment, and a favorable release profile. In vitro experiments using doxorubicin (DOX)-treated H9c2 cardiomyocytes highlighted the superior cellular uptake of NLCs compared to the free solution. Notably, pretreatment with optimized bromelain-coated and uncoated icariin-loaded NLCs significantly improved cell viability and reduced apoptotic rates, indicating their potential role in cardioprotection. The therapeutic effect of NLCs was markedly enhanced relative to free icariin, demonstrating the added value of nano-formulation. Combination index (CI) analysis using Compusyn further verified the synergistic interaction between nano-formulated icariin and bioactive excipients, enabling improved therapeutic outcomes with lower effective doses. These findings highlight the potential of NLC-based delivery systems in counteracting doxorubicin-induced cardiotoxicity, supporting further preclinical studies for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.